Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER)

Share on StockTwits

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reissued by investment analysts at Needham & Company LLC in a research note issued on Wednesday, AnalystRatings.com reports.

OMER has been the topic of several other research reports. Maxim Group set a $32.00 target price on shares of Omeros and gave the stock a “buy” rating in a research report on Friday, August 9th. BidaskClub cut shares of Omeros from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 12th. ValuEngine cut shares of Omeros from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Zacks Investment Research cut shares of Omeros from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, Wedbush reiterated a “hold” rating and issued a $18.00 target price on shares of Omeros in a research note on Monday, October 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. Omeros presently has an average rating of “Hold” and an average target price of $25.60.

Shares of Omeros stock opened at $14.04 on Wednesday. The firm’s 50 day moving average price is $15.54 and its 200-day moving average price is $16.96. Omeros has a 52-week low of $10.30 and a 52-week high of $20.92. The company has a market cap of $669.33 million, a P/E ratio of -6.32 and a beta of 2.78.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.08. The firm had revenue of $29.86 million during the quarter, compared to analysts’ expectations of $27.19 million. During the same period in the previous year, the firm earned ($0.81) EPS. The firm’s quarterly revenue was up 547.7% on a year-over-year basis. As a group, equities research analysts expect that Omeros will post -1.2 earnings per share for the current fiscal year.

In related news, Director Thomas J. Cable sold 5,000 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $15.12, for a total value of $75,600.00. Following the completion of the transaction, the director now directly owns 35,067 shares in the company, valued at approximately $530,213.04. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 12.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bourgeon Capital Management LLC purchased a new stake in shares of Omeros during the third quarter worth $41,000. Aperio Group LLC purchased a new stake in shares of Omeros in the second quarter valued at about $49,000. Paloma Partners Management Co purchased a new stake in shares of Omeros in the second quarter valued at about $180,000. Cetera Advisors LLC purchased a new stake in shares of Omeros in the third quarter valued at about $180,000. Finally, Brighton Jones LLC purchased a new stake in shares of Omeros in the third quarter valued at about $216,000. Hedge funds and other institutional investors own 53.46% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: What moving averages are used to define a golden cross?

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.